

Alpha PRO Tech Ltd. (APT)

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0000884269

Alpha PRO Tech Ltd. APT; healthcare	
Grade	A/B on the A/B boundary of 371 graded peers percentile 19.7; sampling error 2.5 points; lower is stronger
Rank	74 of 371
Profitability	C percentile 52.6
Solvency	A percentile 8.6
Growth and financing	C percentile 52.7
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$74.1M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Mar 11, 2026 212 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	\$5.96 2026-10-08; market equity \$60.8M
Price used in grade	None




A/B, the bull

on the A/B boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: A from Mar 21, 2022, A/B from Mar 21, 2024, A from Mar 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 11, 2026

ALPHA PRO TECH, LTD. ("Alpha Pro Tech," the "Company," "we," "our" or "us") is the parent company of Alpha Pro Tech, Inc. and Alpha ProTech Engineered Products, Inc. The Company was incorporated in the State of Delaware on July 1, 1994, as a successor to a business that was organized in 1983. Our executive offices are located at 53 Wellington Street East, Aurora, Ontario, Canada L4G 1H6, and our telephone number is (905) 479-0654. Our website is located at www.alphaprotech.com. The Company continued to

qualify as a smaller reporting company at the measurement date for determining such qualification during 2025.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 52.6						
Gross profitability		30.4%	32.2%	49.1	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		1.6%	(6.6%)	83.5	811	2025-12-31
Gross margin stability, five years		1.5 pts	2.8 pts	25.2	243	2025-12-31
Solvency, sleeve percentile 8.6						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		12.40	(0.31)	7.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		12.94x	2.96x	10.1	839	2025-12-31
Growth and financing, sleeve percentile 52.7						
Revenue growth, three-year compound		(1.6%)	10.0%	75.1	415	2025-12-31
Free cash flow growth, three-year compound		(23.0%)	10.9%	91.6	96	2025-12-31
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		4.6%	2.1%	41.7	704	2025-12-31
Net share issuance, one year		(6.3%)	2.5%	2.4	634	2026-03-01

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
------	---------	------------	--------	----------

69	Dexcom Inc. (DXCM)	18.4	A/B	fortress balance sheet
70	Orthofix Medical Inc. (OFIX)	18.6	A/B	
71	Adma Biologics, Inc. (ADMA)	18.9	A/B	late filer, fortress balance sheet
72	InnovAge Holding Corp. (INNV)	19.2	A/B	fortress balance sheet
73	Merit Medical Systems Inc. (MMSI)	19.5	A/B	
74	Alpha PRO Tech Ltd. (APT) <	19.7	A/B	
75	Ocular Therapeutix, Inc. (OCUL)	20.0	A/B	dilution
76	Boston Scientific Corp. (BSX)	20.3	A/B	
77	Siga Technologies Inc. (SIGA)	20.5	A/B	fortress balance sheet
78	West Pharmaceutical Services Inc. (WST)	20.8	A/B	fortress balance sheet
79	Rigel Pharmaceuticals Inc. (RIGL)	21.1	A/B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	15.2%	8.0%	55
Distance from 52-week high	(9.6%)	(31.4%)	85
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	2.8%	(1.0%)	69
Book value to price	1.06	0.28	88
Sales to price	0.97	0.31	82
Composite equity issuance, five years	(28.7%)	20.3%	3
Relative strength against the sector, log excess return	(0.07)	(0.14)	55

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$18.9M
Operating cash flow, four quarters	\$6.5M
Months of runway	not finite
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$133,594

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$22.5M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
2	assets	us-gaap:Assets	\$74.1M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
3	net income	us-gaap:NetIncomeLoss	\$3.5M	2025-12-31	2026-03-11	10-K	0001437749-26-007797

4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.4M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
5	assets	us-gaap:Assets	\$73.7M	2024-12-31	2026-03-11	10-K	0001437749-26-007797
6	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$59.1M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
7	gross profit	us-gaap:GrossProfit	\$22.9M	2024-12-31	2026-03-11	10-K	0001437749-26-007797
8	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$57.8M	2024-12-31	2026-03-11	10-K	0001437749-26-007797
9	gross profit	us-gaap:GrossProfit	\$22.8M	2023-12-31	2025-03-12	10-K	0001437749-25-007218
10	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$61.2M	2023-12-31	2025-03-12	10-K	0001437749-25-007218
11	gross profit	us-gaap:GrossProfit	\$21.7M	2022-12-31	2024-03-13	10-K	0001437749-24-007539
12	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$62.0M	2022-12-31	2024-03-13	10-K	0001437749-24-007539
13	gross profit	us-gaap:GrossProfit	\$25.3M	2021-12-31	2023-03-16	10-K	0001437749-23-006845
14	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$68.6M	2021-12-31	2023-03-16	10-K	0001437749-23-006845
15	current assets	us-gaap:AssetsCurrent	\$52.5M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
16	current liabilities	us-gaap:LiabilitiesCurrent	\$4.1M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$48.5M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
18	operating income	us-gaap:OperatingIncomeLoss	\$3.8M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
19	book equity	us-gaap:StockholdersEquity	\$62.5M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
20	liabilities	us-gaap:Liabilities	\$11.7M	2025-12-31	2026-03-11	10-K	0001437749-26-007797
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$639,000	2025-12-31	2026-03-11	10-K	0001437749-26-007797
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$5.7M	2024-12-31	2026-03-11	10-K	0001437749-26-007797
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.8M	2024-12-31	2026-03-11	10-K	0001437749-26-007797
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.5M	2023-12-31	2025-03-12	10-K	0001437749-25-007218
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$792,000	2023-12-31	2025-03-12	10-K	0001437749-25-007218
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$4.3M	2022-12-31	2024-03-13	10-K	0001437749-24-007539
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$492,000	2022-12-31	2024-03-13	10-K	0001437749-24-007539
28	assets	us-gaap:Assets	\$68.8M	2023-12-31	2025-03-12	10-K	0001437749-25-007218
29	assets	us-gaap:Assets	\$64.8M	2022-12-31	2024-03-13	10-K	0001437749-24-007539
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,185,427	2026-03-01	2026-03-11	10-K	0001437749-26-007797
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,873,415	2025-02-28	2025-03-12	10-K	0001437749-25-007218